Search research articles
Contact Us
Filters
Showing results (1-10 of 57) with videos related to
Page
of 6
Sort By:
Risk Management and Healthcare Policy
|
July 25, 2012
Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review
Matteo Ruggeri
Recenti Progressi in Medicina
|
November 27, 2014
[Clinical and economical evaluation of new analgesics for the management of chronic pain]
Flaminia Coluzzi, Matteo Ruggeri
Current Medical Research and Opinion
|
February 18, 2014
Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain
Flaminia Coluzzi, Matteo Ruggeri
Current Medical Research and Opinion
|
October 1, 2014
Comparing tapentadol to oxycodone/naloxone combination: imagining castles in the air … while building sandcastles! Re: Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin 2014;30:1139-51
Flaminia Coluzzi, Matteo Ruggeri
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 21, 2015
Do Probability and Certainty Equivalent Techniques Lead to Inconsistent Results? Evidence from Gambles Involving Life-Years and Quality of Life
Matteo Ruggeri, Silvia Coretti
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 15, 2014
The minimum clinically important difference for EQ-5D index: a critical review
Silvia Coretti, Matteo Ruggeri, Paul McNamee
Expert Review of Pharmacoeconomics & Outcomes Research
|
April 8, 2014
Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain
Matteo Ruggeri, Adriana Turriziani, Marco Oradei
Environmental Science and Pollution Research International
|
March 6, 2022
On the Frontline-A bibliometric Study on Sustainability, Development, Coronaviruses, and COVID-19
Andrea Gatto, Carlo Drago, Matteo Ruggeri
Journal of Health Economics
|
January 8, 2008
Is risk attitude outcome specific within the health domain?
Marjon van der Pol, Matteo Ruggeri
Health Policy (Amsterdam, Netherlands)
|
November 2, 2010
The cost-effectiveness of alternative strategies against HBV in Italy
Matteo Ruggeri, Americo Cicchetti, Antonio Gasbarrini
Page
of 6
Search research articles
Search
Showing results (1-10 of 57) with videos related to
Sort By:
Page
of 6
Risk Management and Healthcare Policy
|
July 25, 2012
Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review
Matteo Ruggeri
Recenti Progressi in Medicina
|
November 27, 2014
[Clinical and economical evaluation of new analgesics for the management of chronic pain]
Flaminia Coluzzi, Matteo Ruggeri
Current Medical Research and Opinion
|
February 18, 2014
Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain
Flaminia Coluzzi, Matteo Ruggeri
Current Medical Research and Opinion
|
October 1, 2014
Comparing tapentadol to oxycodone/naloxone combination: imagining castles in the air … while building sandcastles! Re: Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin 2014;30:1139-51
Flaminia Coluzzi, Matteo Ruggeri
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 21, 2015
Do Probability and Certainty Equivalent Techniques Lead to Inconsistent Results? Evidence from Gambles Involving Life-Years and Quality of Life
Matteo Ruggeri, Silvia Coretti
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 15, 2014
The minimum clinically important difference for EQ-5D index: a critical review
Silvia Coretti, Matteo Ruggeri, Paul McNamee
Expert Review of Pharmacoeconomics & Outcomes Research
|
April 8, 2014
Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain
Matteo Ruggeri, Adriana Turriziani, Marco Oradei
Environmental Science and Pollution Research International
|
March 6, 2022
On the Frontline-A bibliometric Study on Sustainability, Development, Coronaviruses, and COVID-19
Andrea Gatto, Carlo Drago, Matteo Ruggeri
Journal of Health Economics
|
January 8, 2008
Is risk attitude outcome specific within the health domain?
Marjon van der Pol, Matteo Ruggeri
Health Policy (Amsterdam, Netherlands)
|
November 2, 2010
The cost-effectiveness of alternative strategies against HBV in Italy
Matteo Ruggeri, Americo Cicchetti, Antonio Gasbarrini
Page
of 6